CLSA Capital Partners

CLSA Capital Partners, established in 1999, serves as the alternative asset management arm of CLSA, a prominent independent brokerage and investment group based in Hong Kong. The firm specializes in private equity, private credit, and private real estate strategies, focusing on generating value through diverse investment opportunities. CLSA Capital Partners manages several funds, including a buyout fund in collaboration with Shanghai Guosheng Fund that targets sectors such as green technology, commercial products, and financial services within China. Another notable initiative is CLSA Sunrise Capital IV, which is dedicated to investments in Japan. Through these strategies, CLSA Capital Partners aims to leverage its expertise in the Asian markets while delivering attractive returns to its investors.

Cheuk Wing Chan

VP and Investment Manager

David Cheung

CFO

Danny Cheung

Vice President

Yeu Liong Chong

Chief Financial Officer

Hazwan Hadian

Director

Eugene Hsiao

Associate

Peter Kennedy

Managing Director and Head of Clean Resources Fund

Megumi Kiyozuka

Managing Director and Head of Sunrise

Shota Kuwaki

Director - Investor Relations

Angel Li

Head of Portfolio Management

Steven Lin

Associate

Chris Michel

COO of Clean Resources Asia

Peter Min

Managing Director and Head of Pacific Transportation

Jit Meng Ng

Managing Director

Wayne Palmer

Chief Operating Officer

Gregory Park

Managing Director and Head of Lending Ark Asia Secured Private Debt Fund

Andrew Pidden

MD

Naotsugu Saito

MD

Kentaro Sakamoto

Senior Associate

Jeffrey Shi

MD of Property Fund

Vivek Singla

VP

Thomas Tan

MD

Miranda Tang

Managing Director and Head of ARIA

Mitsuhiro Tohya

MD

Hirotaka Uchiyama

Japan Representative and MD

Premal Ved

SVP

Randy Wilbert

Chief Executive Officer

Nicholas Woffinden

Investment Manager

Jamie Yip

Investment Manager

Yuan Yu

Associate

Byron Zhao

Managing Director and Head of China and Taiwan

Past deals in Taiwan

ACT Genomics

Series C in 2018
ACT Genomics Co., Ltd. is a cancer molecular information service company based in Taipei City, Taiwan, with additional locations in Hong Kong, Singapore, and Japan. Established in 2014, the company specializes in transforming cancer genomic information into precision diagnostics and personalized treatment options. Through advanced technologies, including next-generation sequencing and bioinformatics tools, ACT Genomics offers comprehensive tumor profiling that identifies specific genetic alterations driving cancer pathogenesis and treatment responses. Their services include integrated genomic analysis, clinical reporting on genomic alterations and therapeutic implications, and profiling of cancer-related genes. Additionally, ACT Genomics assists in predicting responses to immunotherapy and monitoring tumor burden through circulating tumor DNA detection. The company's innovative approach aims to enhance the effectiveness of oncology treatment decisions, making personalized medicine more accessible and impactful.

Fulltech Fiber Glass

Private Equity Round in 2008
Fulltech Fiber Glass Corp. produces and sells fiber glass yarn and fabrics in Taiwan. It offers electronic grade fiber glass yarn for use in the manufacture of fiber glass fabric, printed circuit boards, desktop and laptop computers, cellular phones, PDAs, and projection cloths, as well as industrial grade fiber glass yarn for use in the manufacture of insulation tubes. The company was founded in 1999 and is based in Taipei, Taiwan.